The effect of low- and high-dose levothyroxine on the expression, protein level, and function of P-glycoprotein in mice The effect of levothyroxine on P-gp is variable
Аннотация
The study was investigated the effect of different doses of levothyroxine on the mRNA expression, protein level and function of Pgp. Mice were divided into 6 groups as control, low dose levothyroxine, high dose levothyroxine, fexofenadine, low dose levothyroxine+fexofenadine and high dose levothyroxine+fexofenadine. Mice received levothyroxine at doses of 8 and 80 µg/kg daily for 21 days. Fexofenadine was administered at dose of 40 mg/kg at the 24 h following the last administration of levothyroxine. The mRNA levels and protein level of Pgp in liver and small intestine were determined by RT-PCR and western blot analysis, respectively. Plasma concentrations of fexofenadine were determined using HPLC. Levothyroxine at low and high doses caused an insignificant increase intestinal mRNA expression of mdr1a, while high dose levothyroxine+fexofenadine caused a significant increase. Levothyroxine caused a dose-dependent decrease in intestinal mRNA expression of mdr1b. In liver, levothyroxine caused a dose-dependent increase in the mRNA expression of mdr1a. Fexofenadine significantly reduced the effect of levothyroxine on mRNA expression of mdr1a in liver. Levothyroxine increased the protein level of Pgp in liver and decrease in intestines. Low dose levothyroxine significantly increased the plasma concentration of fexofenadine. The effects of levothyroxine on the mRNA expression of mdr1a and b in small intestine and liver and protein level of Pgp varied depending on the dose, tissue type, and fexofenadine administration.
Article Details
- Как цитировать
-
Tras, B., Uney, K., Eser Faki, H., Melik Parlak, T., & Ozdemir Kutahya, Z. (2023). The effect of low- and high-dose levothyroxine on the expression, protein level, and function of P-glycoprotein in mice: The effect of levothyroxine on P-gp is variable. Journal of the Hellenic Veterinary Medical Society, 74(3), 6247–6255. https://doi.org/10.12681/jhvms.31421
- Выпуск
- Том 74 № 3 (2023)
- Раздел
- Research Articles
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 4.0 Всемирная.
Authors who publish with this journal agree to the following terms:
· Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
· Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
· Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Скачивания
Данные скачивания пока недоступны.
Библиографические ссылки
Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I.,
and Gottesman, M.M., 1999. Biochemical, cellular, and pharmaco
logical aspects of the multidrug transporter. Annual Review of Phar
macology and Toxicology 39(1): 361-398. doi: 10.1146/annurev.
pharmtox.39.1.361
American Society of Hospital Pharmacists. (2010). AHFS Drug Informa
tion 2010: Bethesda, MD: American Society of Health-System Phar
macists.
Brady, J.M., Cherrington, N.J., Hartley, D.P., Buist, S.C., Li, N., Klaas
sen, C.D. 2002. Tissue distribution and chemical induction of multi
ple drug resistance genes in rats. Drug Metabolism and Disposition
(7): 838-844. doi: 10.1124/dmd.30.7.838
Burk, O., Brenner, S., Hofmann, U., Tegude, H., Igel, S., Schwab, M.,
Eichelbaum, M., and Alscher, M. 2010. The impact of thyroid dis
ease on the regulation, expression, and function of ABCB1 (MDR1/P
glycoprotein) and consequences for the disposition of digoxin. Clin
ical Pharmacology & Therapeutics 88(5): 685-694. doi: 10.1038/
clpt.2010.176
Capen, C.C. 1997. Mechanistic data and risk assessment of selected toxic
end points of the throid gland. Toxicologic Pathology 25(1): 39-48.
doi: 10.1177/019262339702500109
Cetin, G.,Tras, B., and Uney, K. 2021. The effects of P-glycoprotein mod
ulators on the transition of levofloxacin to rat brain, testicle, and plas
ma: In vivo and in silico studies. Chemistry Select 6: 7476-7481. doi:
1002/slct.202102122
Chawla, A., Repa, J.J., Evans, R.M., and Mangelsdorf, D.J. 2001. Nu
clear receptors and lipid physiology: opening the X-files. Science
(5548): 1866-1870. doi: 10.1126/science.294.5548.1866
Cicatiello, A.G., Di Girolamo, D., and Dentice, M. 2018. Metabolic ef
fects of the intracellular regulation of thyroid hormone: old players,
new concepts. Frontiers in Endocrinology 9: 474. doi: 10.3389/fen
do.2018.00474
Cui, Y.J., Cheng, X., Weaver, Y.M., Klaassen, C.D. 2009. Tissue distri
bution, gender-divergent expression, ontogeny, and chemical induc
tion of multidrug resistance transporter genes (mdr1a, mdr1b, mdr2)
in mice. Drug Metabolism and Disposition 37(1): 203-210. doi:
1124/dmd.108.023721
Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R., and Kim, R.B.
OATP and P-glycoprotein transporters mediate the cellular up
take and excretion of fexofenadine. Drug Metabolism and Disposi
tion 27(8): 866-871.
Dickenson, J., Freeman, F, Mills, C.L., Thode, C., Sivasubramaniam, S.
Trasnporter Proteins. Molecular Pharmacology: From DNA to
Drug Discovery. Wiley-Blackwell. pp. 129-74.
Drescher, S., Glaeser, H., Mürdter, T., Hitzl, M., Eichelbaum, M., and
Fromm, M.F. 2003. P‐glycoprotein‐mediated intestinal and biliary
digoxin transport in humans. Clinical Pharmacology & Therapeutics
(3): 223-231. doi: 10.1067/mcp.2003.27
Dresser, G.K., Bailey, D.G., Leake, B.F., Schwarz, U.I., Dawson, P.A.,
Freeman, D.J., and Kim, R.B. 2002. Fruit juices inhibit organic anion
transporting polypeptide-mediated drug uptake to decrease the oral
availability of fexofenadine. Clinical Pharmacology & Therapeutics
(1): 11-20. doi: 10.1067/mcp.2002.121152
Dresser, G.K., Schwarz, U.I., Wilkinson, G.R., and Kim, R.B. 2003. Coor
dinate induction of both cytochrome P4503A and MDR1 by St John’s
wort in healthy subjects. Clinical Pharmacology & Therapeutics
(1): 41-50. doi: 10.1067/mcp.2003.10
Engels, K., Rakov, H., Zwanziger, D., Hönes, G.S., Rehders, M., Brix, K.,
Köhrle, J., Möller, L.C., and Führer, D. 2016. Efficacy of protocols
for induction of chronic hyperthyroidism in male and female mice.
Endocrine 54(1): 47-54. doi: 10.1007/s12020-016-1020-8
Faber, K.N., Müller, M., and Jansen, P.L. 2003. Drug transport proteins
in the liver. Advanced Drug Delivery Reviews 55(1): 107-124. doi:
1016/s0169-409x(02)00173-4
Fernandez, C., Buyse, M., German-Fattal, M., and Gimenez, F. 2004.
Influence of the pro-inflammatory cytokines on P-glycoprotein ex
pression and functionality. Journal of Pharmacy & Pharmaceutical
Sciences 7(3): 359-371.
González-Lobato, L., Real, R., Prieto, J.G., Álvarez, A.I., and Merino,
G. 2010. Differential inhibition of murine Bcrp1/Abcg2 and human
BCRP/ABCG2 by the mycotoxin fumitremorgin C. European Journal
of Pharmacology 644(1-3): 41-48. doi: 10.1016/j.ejphar.2010.07.016
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., Von Richter,
O., Zundler, J., and Kroemer, H.K. 1999. The role of intestinal P-gly
coprotein in the interaction of digoxin and rifampin. The Journal of
Clinical Investigation 104(2): 147-153. doi: 10.1172/JCI6663
Gül, I.G., Eryilmaz, G., and Karamustafalioglu, K.O. 2016. P-glycopro
tein and its Role in Treatment Resistance. Psikiyatride Güncel Yak
laşımlar 8(1): 19-31. doi: 10.5455/cap.20150610111721
Hebert, M.F., Fisher, R.M., Marsh, C.L., Dressler, D., and Bekersky, I.
Effects of rifampin on tacrolimus pharmacokinetics in healthy
volunteers. The Journal of Clinical Pharmacology 39(1): 91-96. doi:
1177/00912709922007499
Ho, R.H., and Kim, R.B. 2005. Transporters and drug therapy: impli
cations for drug disposition and disease. Clinical Pharmacology &
Therapeutics 78(3): 260-277. doi: 10.1016/j.clpt.2005.05.011
Hsu, S.I., Lothstein, L., Horwitz, S.B. 1989. Differential overexpression
of three mdr gene family members in multidrug-resistant J774.2
mouse cells. Evidence that distinct P-glycoprotein precursors are
encoded by unique mdr genes. The Journal of Biological Chemistry
(20): 12053-12062.
https://datasheets.scbt.com/sc-218475.pdf [accessed 12 November 2022].
https://go.drugbank.com/drugs/DB00451 [accessed 11 November 2022].
Jin, M.J., and Han, H.K. 2010. Effect of piperine, a major component of
black pepper, on the intestinal absorption of fexofenadine and its im
plication on food-drug interaction. Journal of Food Science 75(3):
H93-H96. doi: 10.1111/j.1750-3841.2010.01542.x
Kim, M., and Lee, B.C. 2019. Therapeutic effect of Scutellaria baical
ensis on L-Thyroxine-induced hyperthyroidism rats. Evidence-Based
Complementary and Alternative Medicine 2019: 3239649 doi:
1155/2019/3239649
Kirn, R.B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M.F., Dempsey,
P.J., Roden, M.M., Belas, F., Chaudhary, A.K., and Roden, D.M.
Interrelationship between substrates and inhibitors of human
CYP3A and P-glycoprotein. Pharmaceutical Research 16(3): 408
doi: 10.1023/a:1018877803319
Markov, G.V., and Laudet, V. 2011. Origin and evolution of the li
gand-binding ability of nuclear receptors. Molecular and Cellular En
docrinology 334(1-2): 21-30. doi: 10.1016/j.mce.2010.10.017
Matheny, C.J., Lamb, M.W., Brouwer, K.L., and Pollack, G.M. 2001. Phar
macokinetic and pharmacodynamic implications of P‐glycoprotein
modulation. Pharmacotherapy: The Journal of Human Pharmacology
and Drug Therapy 21(7): 778-796. doi: 10.1592/phco.21.9.778.34558
Medwid, S., Li, M.M., Knauer, M.J., Lin, K., Mansell, S.E., Schmerk,
C.L., Zhu, C., Griffin, K.E., Yousif, M.D., and Dresser, G.K. 2019.
Fexofenadine and rosuvastatin pharmacokinetics in mice with tar
geted disruption of organic anion transporting polypeptide 2B1.
Drug Metabolism and Disposition 47(8): 832-842. doi: 10.1124/
dmd.119.087619
Mitin, T., Von Moltke, L.L., Court, M.H., Greenblatt, D.J. 2004. Levothy
roxine up-regulates P-glycoprotein independent of the pregnane X
receptor. Drug Metabolism and Disposition: The Biological Fate of
Chemicals 32(8): 779-782. doi: 10.1124/dmd.32.8.779
Molimard, M., Diquet, B., and Benedetti, M.S. 2004. Comparison of phar
macokinetics and metabolism of desloratadine, fexofenadine, levoce
tirizine and mizolastine in humans. Fundamental & Clinical Pharma
cology 18(4): 399-411. doi: 10.1111/j.1472-8206.2004.00254.x
Mouly, S., and Paine, M.F. 2003. P-glycoprotein increases from proximal
to distal regions of human small intestine. Pharmaceutical Research
(10): 1595-1599. doi: 10.1023/a:1026183200740
Mullur, R., Liu, Y.-Y., and Brent, G.A. 2014. Thyroid hormone regulation
of metabolism. Physiological Reviews 94(2): 355-382. doi: 10.1152/ physrev.00030.2013
Narang, V.S., Fraga, C., Kumar, N., Shen, J., Throm, S., Stewart, C.F.,
and Waters, C.M. 2008. Dexamethasone increases expression and
activity of multidrug resistance transporters at the rat blood-brain
barrier. American Journal of Physiology-Cell Physiology 295(2):
C440-C450. doi: 10.1152/ajpcell.00491.2007
O’Connor, P., and Feely, J. 1987. Clinical pharmacokinetics and endo
crine disorders. Clinical Pharmacokinetics 13(6): 345-364. doi:
2165/00003088-198713060-00001
Shirasaka, Y., Konishi, R., Funami, N., Kadowaki, Y., Nagai, Y., Sakaeda,
T., and Yamashita, S. 2009. Expression levels of human P‐glycopro
tein in In Vitro cell lines: correlation between mRNA and protein lev
els for P‐glycoprotein expressed in cells. Biopharmaceutics & Drug
Disposition 30(3): 149-152. doi: 10.1002/bdd.650
Siegmund, W., Altmannsberger, S., Paneitz, A., Hecker, U., Zschiesche,
M., Franke, G., Meng, W., Warzok, R., Schroeder, E., and Sperker,
B. 2002. Effect of levothyroxine administration on intestinal P‐gly
coprotein expression: consequences for drug disposition. Clini
cal Pharmacology & Therapeutics 72(3): 256-264. doi: 10.1067/
mcp.2002.126706
Simons, F.E.R., and Simons, K.J. 1999. Clinical pharmacology of new
histamine H 1 receptor antagonists. Clinical Pharmacokinetics 36(5):
-352. doi: 10.2165/00003088-199936050-00003
Simpson, K., and Jarvis, B. 2000. Fexofenadine: a review of its use in
the management of seasonal allergic rhinitis and chronic idiopathic
urticaria. Drugs 59(2): 301-321. doi: 10.2165/00003495-200059020
Tanaka, Y., Slitt, A.L., Leazer, T.M., Maher, J.M., and Klaassen, C.D.
Tissue distribution and hormonal regulation of the breast can
cer resistance protein (Bcrp/Abcg2) in rats and mice. Biochemical
and Biophysical Research Communications 326(1): 181-187. doi:
1016/j.bbrc.2004.11.012
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., and
Willingham, M.C. 1987. Cellular localization of the multidrug-resis
tance gene product P-glycoprotein in normal human tissues. Proceed
ings of the National Academy of Sciences 84(21): 7735-7738. doi:
1073/pnas.84.21.7735
Tras, B., Cetin, G., Uney, K., Dik, B., Corum, O., and Atalay, S. 2017.
Effects of BCRP and P-gp Modulators on the Penetration of Aflatox
in B1 into the Mouse Brain. Kafkas Universitesi Veteriner Fakultesi
Dergisi 23(1).
Tras, B., Faki, H.E., Kutahya, Z.O., Bahcivan, E., Dik, B., Bozkurt, B.,
and Uney, K. 2021. Treatment and protective effects of metallopro
teinase inhibitors alone and in combination with N-Acetyl cysteine
plus vitamin E in rats exposed to aflatoxin B1. Toxicon 194: 79-85.
doi: 10.1016/j.toxicon.2021.02.012
Westphal, K., Weinbrenner, A., Zschiesche, M., Franke, G., Knoke, M.,
Oertel, R., Fritz, P., Von Richter, O., Warzok, R., and Hachenberg,
T. 2000. Induction of P‐glycoprotein by rifampin increases intestinal
secretion of talinolol in human beings: a new type of drug/drug inter
action. Clinical Pharmacology & Therapeutics 68(4): 345-355. doi:
1067/mcp.2000.109797
Zong, J., and Pollack, G.M. 2003. Modulation of P-glycoprotein trans
port activity in the mouse blood-brain barrier by rifampin. Journal of
Pharmacology and Experimental Therapeutics 306(2): 556-562. doi:
1124/jpet.103.049452
